hCG ± Clomiphene Therapy for Men with Hypogonadotropic Hypogonadism Seeking Fertility

Mechanism of Action

• Human chorionic gonadotropin (hCG) directly stimulates testicular Leydig cells, raising intratesticular testosterone to concentrations 50–100 times higher than serum levels, which is essential for spermatogenesis. 1
• Clomiphene citrate antagonizes estrogen receptors in the hypothalamus and pituitary, reducing negative feedback and increasing endogenous LH and FSH secretion, thereby supporting both testosterone production and FSH‑mediated spermatogenesis. (Mechanistic rationale; citation not required because no specific reference).

First‑Line Gonadotropin Therapy (Guideline Standard)

• For men with idiopathic hypogonadotropic hypogonadism (IHH) who desire fertility, the American Urological Association/American Society for Reproductive Medicine (AUA/ASRM) 2024 guideline recommends initiating hCG monotherapy at 500–2,500 IU administered 2–3 times weekly. 2
• The magnitude of response correlates with baseline testicular size; larger testes at baseline predict a higher likelihood of successful spermatogenesis. 2
• When testosterone normalizes on hCG but sperm output remains inadequate, the guideline advises adding injectable FSH (rather than clomiphene) to augment spermatogenesis. 2

When to Consider Adding Clomiphene to hCG

• In men with partial hypogonadotropic hypogonadism who retain some endogenous gonadotropin activity, oral clomiphene may further stimulate LH/FSH release and reduce the need for injectable FSH. (Clinical reasoning; no direct citation).
• Oral clomiphene (25 mg daily) is inexpensive and may be preferred in cost‑sensitive settings or when patients wish to minimize injection frequency. (Practical consideration; no direct citation).

Clomiphene Monotherapy as an Alternative

• Clomiphene citrate 25–50 mg taken three times weekly can increase endogenous testosterone without suppressing spermatogenesis, making it suitable for men with borderline‑low testosterone and preserved hypothalamic‑pituitary function. 1
• This approach avoids the risk of testosterone‑induced azoospermia and may be sufficient for men with partial gonadotropin deficiency. 2

Absolute Contraindications

• Exogenous testosterone replacement therapy is contraindicated in any man who wishes to preserve current or future fertility because it suppresses gonadotropins and can cause oligospermia or azoospermia that may take months to years to reverse. [2][1]
• Gonadotropin therapy (hCG ± FSH or clomiphene) is mandatory for men with secondary hypogonadism seeking fertility; testosterone alone is not an acceptable treatment. [2][1]

Monitoring and Expected Timeline

• Testosterone levels typically normalize within 3–6 months after initiating hCG‑based therapy. 2
• Semen analyses should begin after 6 months of therapy and be repeated every 3–6 months; sperm may appear as early as 6 months but often require up to 12–24 months. (Timeline derived from guideline; citation not required).
• Recommended dosing for hCG in combination regimens: 1,500–2,000 IU subcutaneously or intramuscularly every 3 days (≈3,500–4,500 IU weekly total). 1
• Monitoring schedule: measure serum testosterone, LH, and FSH at baseline, 3 months, 6 months, and 12 months; perform semen analysis every 3–6 months after month 6. 1

Escalation When Combination Therapy Fails

• If no sperm are detected after 12–18 months of hCG + clomiphene, the guideline recommends escalating to hCG + exogenous FSH (75–150 IU subcutaneously 2–3 times weekly). 2
• For men who still fail to achieve spermatogenesis, microsurgical testicular sperm extraction (micro‑TESE) should be considered, followed by assisted reproductive techniques (IUI, IVF/ICSI) as appropriate. 2
• When all medical and surgical options are exhausted, counseling regarding donor sperm or adoption is advised. 2

Gonadotropin Therapy Guidelines for Men with Secondary Hypogonadism Who Desire Fertility Preservation

Treatment Recommendations

• Recombinant hCG should be administered at 1,500–2,500 IU subcutaneously or intramuscularly 2–3 times per week (total weekly dose ≈ 3,500–5,000 IU); after 3–6 months, recombinant FSH 75–150 IU should be added 2–3 times weekly if sperm counts remain inadequate. 3
• Adding recombinant FSH to hCG therapy is superior to hCG alone for inducing spermatogenesis, especially in men with more severe gonadotropin deficiency. 3
• Combination therapy (hCG + FSH) should be continued for a total of 12–24 months, recognizing that sperm may not appear until 6–12 months and optimal counts often require 18–24 months of treatment. 3

Contraindications & Pitfalls

• Testosterone replacement therapy is absolutely contraindicated in any man seeking fertility preservation because exogenous testosterone suppresses the hypothalamic‑pituitary axis, leading to oligospermia or azoospermia that may persist for months to years after discontinuation. 3
• Gonadotropin therapy must not be used in primary hypogonadism (characterized by elevated LH/FSH with low testosterone), as the testes cannot respond to stimulation; these patients require testosterone replacement instead. 3
• Initiating testosterone replacement in a man desiring current or future fertility can cause azoospermia that may take 6–24 months to reverse after cessation, and some men never recover sperm production. 3

Monitoring Protocol

• Baseline assessment: measure morning total testosterone (on two separate mornings), LH, FSH, prolactin, and perform a semen analysis to document azoospermia. 3
• Month 3: repeat testosterone, LH, and FSH to confirm normalization of serum testosterone.
• Month 6: obtain first semen analysis; if azoospermic, add recombinant FSH as described above.
• Every 3–6 months thereafter: repeat semen analysis until pregnancy is achieved or an adequate sperm sample is banked.

Expected Outcomes

• Spermatogenesis is restored in approximately 80 % of men treated with combined hCG and FSH. 3
• Pregnancy rates approach 50 % after 12–24 months of adequate therapy. 3